Impact of Pretransplantation 18F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma

Veronika Bachanova, Linda J. Burns, Kwang Woo Ahn, Ginna G. Laport, Görgün Akpek, Mohamed A. Kharfan-Dabaja, Taiga Nishihori, Edward Agura, Philippe Armand, Samantha M. Jaglowski, Mitchell S. Cairo, Amanda F. Cashen, Jonathon B. Cohen, Anita D'Souza, César O. Freytes, Robert Peter Gale, Siddhartha Ganguly, Nilanjan Ghosh, Leona A. Holmberg, David J. InwardsAbraham S. Kanate, Hillard M. Lazarus, Adriana K. Malone, Reinhold Munker, Alberto Mussetti, Maxim Norkin, Tim D. Prestidge, Jacob M. Rowe, Prakash Satwani, Tanya Siddiqi, Patrick J. Stiff, Basem M. William, Baldeep Wirk, David G. Maloney, Sonali M. Smith, Anna M. Sureda, Jeanette Carreras, Mehdi Hamadani

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Assessment with 18F-fluorodeoxy glucose (FDG)-positron emission tomography (PET) before hematopoietic cell transplantation (HCT) for lymphoma may be prognostic for outcomes. Patients with chemotherapy-sensitive non-Hodgkin lymphoma (NHL) undergoing allogeneic HCT reported to the Center of International Blood and Marrow Transplantation Registry between 2007 and 2012 were included. Pre-HCT PET status (positive versus negative) was determined by the reporting transplantation centers. We analyzed 336 patients; median age was 55 years and 60% were males. Follicular lymphoma (n = 104) was more common than large cell (n = 85), mantle cell (n = 69), and mature natural killer or T cell lymphoma (n = 78); two thirds of the cohort received reduced-intensity conditioning; one half had unrelated donor grafts. Patients underwent PET scanning a median of 1 month (range, .07 to 2.83 months) before HCT; 159 were PET positive and 177 were PET negative. At 3 years, relapse/progression, progression-free survival (PFS), and overall survival (OS) in PET-positive versus PET-negative groups were 40% versus 26%; P = .007; 43% versus 47%; P = .47; and 58% versus 60%; P = .73, respectively. On multivariate analysis, a positive pretransplantation PET was associated with an increased risk of relapse/progression (risk ratio [RR], 1.86; P = .001) but was not associated with increased mortality (RR, 1.29, 95% confidence interval [CI], .96 to 1.7; P = .08), therapy failure (RR, 1.32; 95% CI, .95 to 1.84; P = .10), or nonrelapse mortality (RR, .75; 95% CI, .48 to 1.18; P = .22). PET status conferred no influence on graft-versus-host disease. A positive PET scan before HCT is associated with increased relapse risk but should not be interpreted as a barrier to a successful allograft. PET status does not appear to predict survival after allogeneic HCT for NHL.

Original languageEnglish
Pages (from-to)1605-1611
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume21
Issue number9
DOIs
Publication statusPublished - Sep 1 2015

Fingerprint

Cell Transplantation
Positron-Emission Tomography
Non-Hodgkin's Lymphoma
Glucose
Odds Ratio
Confidence Intervals
Recurrence
Transplantation
Unrelated Donors
Follicular Lymphoma
Natural Killer T-Cells
Survival
Mortality
T-Cell Lymphoma
Graft vs Host Disease
Disease-Free Survival
Allografts
Registries
Lymphoma
Multivariate Analysis

Keywords

  • Allogeneic transplantation
  • Non-Hodgkin lymphoma
  • Positron emission tomography

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Impact of Pretransplantation 18F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. / Bachanova, Veronika; Burns, Linda J.; Ahn, Kwang Woo; Laport, Ginna G.; Akpek, Görgün; Kharfan-Dabaja, Mohamed A.; Nishihori, Taiga; Agura, Edward; Armand, Philippe; Jaglowski, Samantha M.; Cairo, Mitchell S.; Cashen, Amanda F.; Cohen, Jonathon B.; D'Souza, Anita; Freytes, César O.; Gale, Robert Peter; Ganguly, Siddhartha; Ghosh, Nilanjan; Holmberg, Leona A.; Inwards, David J.; Kanate, Abraham S.; Lazarus, Hillard M.; Malone, Adriana K.; Munker, Reinhold; Mussetti, Alberto; Norkin, Maxim; Prestidge, Tim D.; Rowe, Jacob M.; Satwani, Prakash; Siddiqi, Tanya; Stiff, Patrick J.; William, Basem M.; Wirk, Baldeep; Maloney, David G.; Smith, Sonali M.; Sureda, Anna M.; Carreras, Jeanette; Hamadani, Mehdi.

In: Biology of Blood and Marrow Transplantation, Vol. 21, No. 9, 01.09.2015, p. 1605-1611.

Research output: Contribution to journalArticle

Bachanova, V, Burns, LJ, Ahn, KW, Laport, GG, Akpek, G, Kharfan-Dabaja, MA, Nishihori, T, Agura, E, Armand, P, Jaglowski, SM, Cairo, MS, Cashen, AF, Cohen, JB, D'Souza, A, Freytes, CO, Gale, RP, Ganguly, S, Ghosh, N, Holmberg, LA, Inwards, DJ, Kanate, AS, Lazarus, HM, Malone, AK, Munker, R, Mussetti, A, Norkin, M, Prestidge, TD, Rowe, JM, Satwani, P, Siddiqi, T, Stiff, PJ, William, BM, Wirk, B, Maloney, DG, Smith, SM, Sureda, AM, Carreras, J & Hamadani, M 2015, 'Impact of Pretransplantation 18F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma', Biology of Blood and Marrow Transplantation, vol. 21, no. 9, pp. 1605-1611. https://doi.org/10.1016/j.bbmt.2015.05.007
Bachanova, Veronika ; Burns, Linda J. ; Ahn, Kwang Woo ; Laport, Ginna G. ; Akpek, Görgün ; Kharfan-Dabaja, Mohamed A. ; Nishihori, Taiga ; Agura, Edward ; Armand, Philippe ; Jaglowski, Samantha M. ; Cairo, Mitchell S. ; Cashen, Amanda F. ; Cohen, Jonathon B. ; D'Souza, Anita ; Freytes, César O. ; Gale, Robert Peter ; Ganguly, Siddhartha ; Ghosh, Nilanjan ; Holmberg, Leona A. ; Inwards, David J. ; Kanate, Abraham S. ; Lazarus, Hillard M. ; Malone, Adriana K. ; Munker, Reinhold ; Mussetti, Alberto ; Norkin, Maxim ; Prestidge, Tim D. ; Rowe, Jacob M. ; Satwani, Prakash ; Siddiqi, Tanya ; Stiff, Patrick J. ; William, Basem M. ; Wirk, Baldeep ; Maloney, David G. ; Smith, Sonali M. ; Sureda, Anna M. ; Carreras, Jeanette ; Hamadani, Mehdi. / Impact of Pretransplantation 18F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. In: Biology of Blood and Marrow Transplantation. 2015 ; Vol. 21, No. 9. pp. 1605-1611.
@article{c425a4e432514c8cbde7866f05232d7e,
title = "Impact of Pretransplantation 18F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma",
abstract = "Assessment with 18F-fluorodeoxy glucose (FDG)-positron emission tomography (PET) before hematopoietic cell transplantation (HCT) for lymphoma may be prognostic for outcomes. Patients with chemotherapy-sensitive non-Hodgkin lymphoma (NHL) undergoing allogeneic HCT reported to the Center of International Blood and Marrow Transplantation Registry between 2007 and 2012 were included. Pre-HCT PET status (positive versus negative) was determined by the reporting transplantation centers. We analyzed 336 patients; median age was 55 years and 60{\%} were males. Follicular lymphoma (n = 104) was more common than large cell (n = 85), mantle cell (n = 69), and mature natural killer or T cell lymphoma (n = 78); two thirds of the cohort received reduced-intensity conditioning; one half had unrelated donor grafts. Patients underwent PET scanning a median of 1 month (range, .07 to 2.83 months) before HCT; 159 were PET positive and 177 were PET negative. At 3 years, relapse/progression, progression-free survival (PFS), and overall survival (OS) in PET-positive versus PET-negative groups were 40{\%} versus 26{\%}; P = .007; 43{\%} versus 47{\%}; P = .47; and 58{\%} versus 60{\%}; P = .73, respectively. On multivariate analysis, a positive pretransplantation PET was associated with an increased risk of relapse/progression (risk ratio [RR], 1.86; P = .001) but was not associated with increased mortality (RR, 1.29, 95{\%} confidence interval [CI], .96 to 1.7; P = .08), therapy failure (RR, 1.32; 95{\%} CI, .95 to 1.84; P = .10), or nonrelapse mortality (RR, .75; 95{\%} CI, .48 to 1.18; P = .22). PET status conferred no influence on graft-versus-host disease. A positive PET scan before HCT is associated with increased relapse risk but should not be interpreted as a barrier to a successful allograft. PET status does not appear to predict survival after allogeneic HCT for NHL.",
keywords = "Allogeneic transplantation, Non-Hodgkin lymphoma, Positron emission tomography",
author = "Veronika Bachanova and Burns, {Linda J.} and Ahn, {Kwang Woo} and Laport, {Ginna G.} and G{\"o}rg{\"u}n Akpek and Kharfan-Dabaja, {Mohamed A.} and Taiga Nishihori and Edward Agura and Philippe Armand and Jaglowski, {Samantha M.} and Cairo, {Mitchell S.} and Cashen, {Amanda F.} and Cohen, {Jonathon B.} and Anita D'Souza and Freytes, {C{\'e}sar O.} and Gale, {Robert Peter} and Siddhartha Ganguly and Nilanjan Ghosh and Holmberg, {Leona A.} and Inwards, {David J.} and Kanate, {Abraham S.} and Lazarus, {Hillard M.} and Malone, {Adriana K.} and Reinhold Munker and Alberto Mussetti and Maxim Norkin and Prestidge, {Tim D.} and Rowe, {Jacob M.} and Prakash Satwani and Tanya Siddiqi and Stiff, {Patrick J.} and William, {Basem M.} and Baldeep Wirk and Maloney, {David G.} and Smith, {Sonali M.} and Sureda, {Anna M.} and Jeanette Carreras and Mehdi Hamadani",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.bbmt.2015.05.007",
language = "English",
volume = "21",
pages = "1605--1611",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Impact of Pretransplantation 18F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma

AU - Bachanova, Veronika

AU - Burns, Linda J.

AU - Ahn, Kwang Woo

AU - Laport, Ginna G.

AU - Akpek, Görgün

AU - Kharfan-Dabaja, Mohamed A.

AU - Nishihori, Taiga

AU - Agura, Edward

AU - Armand, Philippe

AU - Jaglowski, Samantha M.

AU - Cairo, Mitchell S.

AU - Cashen, Amanda F.

AU - Cohen, Jonathon B.

AU - D'Souza, Anita

AU - Freytes, César O.

AU - Gale, Robert Peter

AU - Ganguly, Siddhartha

AU - Ghosh, Nilanjan

AU - Holmberg, Leona A.

AU - Inwards, David J.

AU - Kanate, Abraham S.

AU - Lazarus, Hillard M.

AU - Malone, Adriana K.

AU - Munker, Reinhold

AU - Mussetti, Alberto

AU - Norkin, Maxim

AU - Prestidge, Tim D.

AU - Rowe, Jacob M.

AU - Satwani, Prakash

AU - Siddiqi, Tanya

AU - Stiff, Patrick J.

AU - William, Basem M.

AU - Wirk, Baldeep

AU - Maloney, David G.

AU - Smith, Sonali M.

AU - Sureda, Anna M.

AU - Carreras, Jeanette

AU - Hamadani, Mehdi

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Assessment with 18F-fluorodeoxy glucose (FDG)-positron emission tomography (PET) before hematopoietic cell transplantation (HCT) for lymphoma may be prognostic for outcomes. Patients with chemotherapy-sensitive non-Hodgkin lymphoma (NHL) undergoing allogeneic HCT reported to the Center of International Blood and Marrow Transplantation Registry between 2007 and 2012 were included. Pre-HCT PET status (positive versus negative) was determined by the reporting transplantation centers. We analyzed 336 patients; median age was 55 years and 60% were males. Follicular lymphoma (n = 104) was more common than large cell (n = 85), mantle cell (n = 69), and mature natural killer or T cell lymphoma (n = 78); two thirds of the cohort received reduced-intensity conditioning; one half had unrelated donor grafts. Patients underwent PET scanning a median of 1 month (range, .07 to 2.83 months) before HCT; 159 were PET positive and 177 were PET negative. At 3 years, relapse/progression, progression-free survival (PFS), and overall survival (OS) in PET-positive versus PET-negative groups were 40% versus 26%; P = .007; 43% versus 47%; P = .47; and 58% versus 60%; P = .73, respectively. On multivariate analysis, a positive pretransplantation PET was associated with an increased risk of relapse/progression (risk ratio [RR], 1.86; P = .001) but was not associated with increased mortality (RR, 1.29, 95% confidence interval [CI], .96 to 1.7; P = .08), therapy failure (RR, 1.32; 95% CI, .95 to 1.84; P = .10), or nonrelapse mortality (RR, .75; 95% CI, .48 to 1.18; P = .22). PET status conferred no influence on graft-versus-host disease. A positive PET scan before HCT is associated with increased relapse risk but should not be interpreted as a barrier to a successful allograft. PET status does not appear to predict survival after allogeneic HCT for NHL.

AB - Assessment with 18F-fluorodeoxy glucose (FDG)-positron emission tomography (PET) before hematopoietic cell transplantation (HCT) for lymphoma may be prognostic for outcomes. Patients with chemotherapy-sensitive non-Hodgkin lymphoma (NHL) undergoing allogeneic HCT reported to the Center of International Blood and Marrow Transplantation Registry between 2007 and 2012 were included. Pre-HCT PET status (positive versus negative) was determined by the reporting transplantation centers. We analyzed 336 patients; median age was 55 years and 60% were males. Follicular lymphoma (n = 104) was more common than large cell (n = 85), mantle cell (n = 69), and mature natural killer or T cell lymphoma (n = 78); two thirds of the cohort received reduced-intensity conditioning; one half had unrelated donor grafts. Patients underwent PET scanning a median of 1 month (range, .07 to 2.83 months) before HCT; 159 were PET positive and 177 were PET negative. At 3 years, relapse/progression, progression-free survival (PFS), and overall survival (OS) in PET-positive versus PET-negative groups were 40% versus 26%; P = .007; 43% versus 47%; P = .47; and 58% versus 60%; P = .73, respectively. On multivariate analysis, a positive pretransplantation PET was associated with an increased risk of relapse/progression (risk ratio [RR], 1.86; P = .001) but was not associated with increased mortality (RR, 1.29, 95% confidence interval [CI], .96 to 1.7; P = .08), therapy failure (RR, 1.32; 95% CI, .95 to 1.84; P = .10), or nonrelapse mortality (RR, .75; 95% CI, .48 to 1.18; P = .22). PET status conferred no influence on graft-versus-host disease. A positive PET scan before HCT is associated with increased relapse risk but should not be interpreted as a barrier to a successful allograft. PET status does not appear to predict survival after allogeneic HCT for NHL.

KW - Allogeneic transplantation

KW - Non-Hodgkin lymphoma

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=84938993122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938993122&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2015.05.007

DO - 10.1016/j.bbmt.2015.05.007

M3 - Article

AN - SCOPUS:84938993122

VL - 21

SP - 1605

EP - 1611

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 9

ER -